New Wilson Disease Therapy Data to Be Presented
People with Wilson disease will see Phase 3 ALXN1840 results at a major liver meeting this November.
Updated on Nov. 2, 2026 in Diseases — General

Monopar Therapeutics will present two abstracts on its investigational therapy ALXN1840 for Wilson disease at AASLD - The Liver Meeting 2026 in Denver, held November 5-9, 2026. The presentations cover baseline disease characteristics from a Phase 3 trial and molybdenum balance in treated patients, relevant to people living with this rare inherited copper-storage disorder.
Why it matters
Wilson disease is a rare inherited condition in which excess copper builds up in the body, and treatment options are limited, so new data on an investigational therapy draws attention from clinicians and patients alike. The conference presentations give the medical community a closer look at the trial population and how the drug affects copper balance ahead of any regulatory decision.
The Phase 3 pivotal trial of ALXN1840 met its primary endpoint over 48 weeks in both previously treated and untreated patients, with durable clinical improvement observed across 645 patient-years of follow-up in 266 patients. The presentations at the conference will provide further detail on baseline characteristics and molybdenum balance, though the magnitude of the primary endpoint effect is not stated in the source.
The players
Monopar Therapeutics
A clinical-stage company developing ALXN1840 as an investigational treatment for Wilson disease.
Frederick K. Askari
A presenter delivering an oral presentation on baseline characteristics from the Phase 3 FoCus trial of ALXN1840.
Professor Aftab Ala
A London-based researcher presenting a poster on molybdenum balance in patients treated with ALXN1840.
AASLD
The American Association for the Study of Liver Diseases, which hosts The Liver Meeting, a major annual conference on liver disease research and care.
The details
ALXN1840 works by rapidly mobilizing excess copper and tightly binding it in albumin complexes, which improves copper balance by increasing how much copper the body excretes in feces. Wilson disease is caused by mutations in the ATP7B gene, which disrupts the normal handling of copper in the liver and elsewhere. The upcoming oral and poster presentations will examine baseline disease characteristics from the Phase 3 FoCus trial and how the therapy shifts molybdenum balance in treated patients.
Timeline
Nov. 5, 2026: Professor Aftab Ala's poster on molybdenum balance begins at AASLD 2026.
Nov. 5-9, 2026: AASLD - The Liver Meeting 2026 takes place in Denver.
Nov. 8, 2026: Frederick K. Askari delivers an oral presentation on baseline Wilson disease characteristics.
Health Landscape
Wilson disease has long been managed with chelating agents and zinc therapy, and ALXN1840 is being evaluated as a newer approach that targets copper directly through excretion. The Phase 3 FoCus trial results add to a limited pipeline of investigational treatments for this rare genetic copper disorder.
If you or a family member has been diagnosed with Wilson disease, the trial data presented at this conference are worth discussing with your hepatologist or treating physician. Anyone with unexplained liver, neurological, or psychiatric symptoms should raise the possibility of copper-related disorders with their doctor, since early recognition matters for management.
The takeaway
Wilson disease is rare, affecting roughly 1 in 30,000 people, but its symptoms can be recognized and treated when identified early. Ask your doctor about copper-related testing if liver or neurological symptoms are unexplained, and follow the presentations at AASLD 2026 for further detail on ALXN1840.
What happens next
Presentation materials will be made available in the Investors section of Monopar's website following each presentation, and regulatory and approval developments for ALXN1840 remain pending.
Further reading
For more context on how conditions like this are tracked and studied, explore our Diseases — General coverage.


